ロード中...
Treatment-related adverse events and response rate to immune checkpoint inhibition
BACKGROUND: Immune checkpoint inhibition (ICI) represents a novel treatment modality for refractory cancers, and improving prediction of potential responders is critical. METHOD: We hypothesized that ICI is a systemic-effecting mechanism. The objective response rate (ORR) for anti-PD-1, anti-PD-L1,...
保存先:
| 出版年: | J Int Med Res |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7783260/ https://ncbi.nlm.nih.gov/pubmed/31777292 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0300060519886454 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|